Table 1.
Baseline Characteristics of Chronic HBV participants stratified by MAFLD.
| The Entire Cohort (n = 2032) | |||
|---|---|---|---|
| Non-MAFLD (n = 1144) | MAFLD (n = 888) | p-Value | |
| Age | 0.355 | ||
| 55.1 (8.8) | 54.8 (8.4) | ||
| Sex | <0.001 | ||
| Male | 788 (68.9%) | 795 (89.5%) | |
| Female | 356 (31.1%) | 93 (10.5%) | |
| Hypertension | <0.001 | ||
| No | 768 (67.1%) | 448 (50.4%) | |
| Yes | 376 (32.9%) | 440 (49.6%) | |
| Diabetes | <0.001 | ||
| No | 900 (78.7%) | 572 (64.4%) | |
| Yes | 244 (21.3%) | 316 (35.6%) | |
| Dyslipidemia | 0.007 | ||
| No | 871 (76.1%) | 629 (70.8%) | |
| Yes | 273 (23.9%) | 259 (29.2%) | |
| Liver cirrhosis | 0.955 | ||
| No | 407 (35.6%) | 317 (35.7%) | |
| Yes | 737 (64.4%) | 571 (64.3%) | |
| Metformin use | <0.001 | ||
| No | 1013 (88.6%) | 697 (78.4%) | |
| Yes | 131 (11.4%) | 191 (21.5%) | |
| Statin use | <0.001 | ||
| No | 1009 (88.2%) | 697 (78.5%) | |
| Yes | 135 (11.8%) | 191 (21.5%) | |
| Antiviral therapy | 0.292 | ||
| No | 243 (21.2%) | 206 (23.2%) | |
| Yes | 901 (78.8%) | 682 (76.8%) | |
| Smoking history | <0.001 | ||
| Non-smoker | 564 (49.3%) | 296 (33.3%) | |
| Ex-smoker | 303 (26.5%) | 274 (30.9%) | |
| Current smoker | 277 (24.2%) | 318 (35.8%) | |
| Alcohol drink | <0.001 | ||
| None | 805 (70.4%) | 405 (45.6%) | |
| Moderate | 247 (21.6%) | 276 (31.1%) | |
| Heavy | 92 (8.0%) | 207 (23.3%) | |
| Physical activity | 0.037 | ||
| 0 to <3 METs-hour/week | 344 (30.1%) | 297 (33.4%) | |
| 3 to <9 METs-hour/week | 272 (23.8%) | 202 (22.8%) | |
| 9 to <18 METs-hour/week | 330 (28.8%) | 273 (30.7%) | |
| ≥18 METs-hour/week | 198 (17.3%) | 116 (13.1%) | |
Abbreviation: MAFLD, metabolic dysfunction-associated fatty liver disease; HBV, hepatitis B virus.